Rgenta Therapeutics has secured approval for its investigational new drug (IND) application for RGT-61159, an oral small molecule RNA modulator, to treat a range of cancers. The approval from the US Food and Drug Administration (FDA) will allow the company to start its first-in-human Phase Ia/Ib clinical trial of the therapy. The gold standard of business intelligence.
RGT-61159 is being developed to treat adenoid cystic carcinoma (ACC), colorectal cancer (CRC), acute myeloid leukemia (AML) and other solid tumours. It targets RNA splicing to inhibit the production of the oncogenic MYB protein. This inhibition could stop the proliferation, or induce the death, of cancer cells that overexpress MYB.
The aberrant expression of MYB is a common factor in human cancers such as ACC, AML and CRC. Rgenta co-founder and CEO Simon Xi said: “Clearance of our first IND application is a significant milestone in Rgenta’s mission to develop oral, small molecule RNA-targeting medicines to treat previously incurable diseases. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form “We look forward to initiating clinical studies of RGT-61159 with a first-in-h.
